The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051871 · Cited by 880
Self-citationThompson, M. A., Aberg, J. A., Cahn, P., Montaner, J. S. G., Rizzardini, G., Telenti, A., Gatell, J. M., Günthard, H. F., Hammer, S. M., Hirsch, M. S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1004 · Cited by 722
van Leth, F., Phanuphak, P., Ruxrungtham, K., Baraldi, E., Miller, S., Gazzard, B., Cahn, P., Lalloo, U., van der Westhuizen, I., Malan, D., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15997-7 · Cited by 684
Lennox, J. L., DeJesus, E., Lazzarin, A., Pollard, R. B., Madruga, J. V. R., Berger, D. S., Zhao, J., Xu, X., Williams-Diaz, A., Rodgers, A. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60918-1 · Cited by 625
Self-citationMolina, J.-M., Cahn, P., Grinsztejn, B., Lazzarin, A., Mills, A., Saag, M., Supparatpinyo, K., Walmsley, S., Crauwels, H., Rimsky, L. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60936-7 · Cited by 405
Self-citationCohen, C. J., Andrade-Villanueva, J., Clotet, B., Fourie, J., Johnson, M. A., Ruxrungtham, K., Wu, H., Zorrilla, C., Crauwels, H., Rimsky, L. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60983-5 · Cited by 374
Self-citationDeJesus, E., Rockstroh, J. K., Henry, K., Molina, J.-M., Gathe, J., Ramanathan, S., Wei, X., Yale, K., Szwarcberg, J., White, K., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60918-0 · Cited by 347
Self-citation
Cited by
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Self-citationClotet, B., Feinberg, J., van Lunzen, J., Khuong-Josses, M.-A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60084-2 · Cited by 507
Nachega, J. B., Parienti, J.-J., Uthman, O. A., Gross, R., Dowdy, D. W., Sax, P. E., Gallant, J. E., Mugavero, M. J., Mills, E. J., & Giordano, T. P. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu046 · Cited by 357
Self-citationThe lifetime medical cost savings from preventing HIV in the United States
Schackman, B. R., Fleishman, J. A., Su, A. E., Berkowitz, B. K., Moore, R. D., Walensky, R. P., Becker, J. E., Voss, C., Paltiel, A. D., Weinstein, M. C., et al. (2015) · Medical Care · doi:10.1097/mlr.0000000000000308 · Cited by 123
Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
Smith, S. J., Zhao, X. Z., Burke, T. R., & Hughes, S. H. (2018) · Retrovirology · doi:10.1186/s12977-018-0420-7 · Cited by 114
Metadata
- Authors
- Sax, P. E., DeJesus, E., Mills, A., Zolopa, A., Cohen, C., Wohl, D., Gallant, J. E., Liu, H. C., Zhong, L., Yale, K., White, K., Kearney, B. P., Szwarcberg, J., Quirk, E., & Cheng, A. K.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 379
- Issue
- 9835
- Pages
- 2439-2448
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2145467751
- Cited by
- 444
- References
- 26
- FWCI
- 44.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. https://app.cochat.ai/papers/10.1016/s0140-6736(12)60917-9
- The paper
- Sax, P. E., DeJesus, E., Mills, A., Zolopa, A., Cohen, C., Wohl, D., Gallant, J. E., Liu, H. C., Zhong, L., Yale, K., White, K., Kearney, B. P., Szwarcberg, J., Quirk, E., & Cheng, A. K. (2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. The Lancet. https://doi.org/10.1016/s0140-6736(12)60917-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
